EP3538114A1 - Methods of using human mesenchymal stem cells to effect cellular and humoral immunity - Google Patents
Methods of using human mesenchymal stem cells to effect cellular and humoral immunityInfo
- Publication number
- EP3538114A1 EP3538114A1 EP17812104.2A EP17812104A EP3538114A1 EP 3538114 A1 EP3538114 A1 EP 3538114A1 EP 17812104 A EP17812104 A EP 17812104A EP 3538114 A1 EP3538114 A1 EP 3538114A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- subject
- mesenchymal stem
- stem cells
- population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 303
- 238000000034 method Methods 0.000 title claims abstract description 86
- 230000004727 humoral immunity Effects 0.000 title claims description 10
- 230000007969 cellular immunity Effects 0.000 title claims description 9
- 230000000694 effects Effects 0.000 title description 14
- 230000000735 allogeneic effect Effects 0.000 claims abstract description 226
- 208000036119 Frailty Diseases 0.000 claims abstract description 62
- 230000032683 aging Effects 0.000 claims abstract description 62
- 206010003549 asthenia Diseases 0.000 claims abstract description 62
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims abstract description 50
- 208000024891 symptom Diseases 0.000 claims abstract description 43
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 133
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 127
- 210000002966 serum Anatomy 0.000 claims description 118
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 117
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 116
- 230000007423 decrease Effects 0.000 claims description 101
- 210000004027 cell Anatomy 0.000 claims description 85
- 230000001684 chronic effect Effects 0.000 claims description 49
- 210000001806 memory b lymphocyte Anatomy 0.000 claims description 43
- 230000003834 intracellular effect Effects 0.000 claims description 42
- 238000011282 treatment Methods 0.000 claims description 42
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 39
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 39
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 30
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 30
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 30
- 238000003556 assay Methods 0.000 claims description 30
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims description 29
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 29
- 102100027207 CD27 antigen Human genes 0.000 claims description 27
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 27
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims description 26
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims description 26
- 239000000090 biomarker Substances 0.000 claims description 26
- 238000002347 injection Methods 0.000 claims description 13
- 239000007924 injection Substances 0.000 claims description 13
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 11
- 239000003550 marker Substances 0.000 claims description 11
- 238000000338 in vitro Methods 0.000 claims description 10
- 238000001802 infusion Methods 0.000 claims description 8
- 230000036039 immunity Effects 0.000 claims description 7
- 210000002950 fibroblast Anatomy 0.000 claims description 6
- 230000007380 inflammaging Effects 0.000 claims description 6
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 5
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 5
- 210000001185 bone marrow Anatomy 0.000 claims description 5
- 238000011156 evaluation Methods 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 4
- 230000002431 foraging effect Effects 0.000 claims description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 claims 1
- 230000008859 change Effects 0.000 description 13
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 12
- 239000000203 mixture Substances 0.000 description 10
- 210000000130 stem cell Anatomy 0.000 description 10
- 239000000902 placebo Substances 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 101100351020 Mus musculus Pax5 gene Proteins 0.000 description 6
- 101100351021 Xenopus laevis pax5 gene Proteins 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 102000046949 human MSC Human genes 0.000 description 5
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000035479 physiological effects, processes and functions Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102100022433 Single-stranded DNA cytosine deaminase Human genes 0.000 description 3
- 101710143275 Single-stranded DNA cytosine deaminase Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102100037504 Paired box protein Pax-5 Human genes 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102100024207 Transcription factor COE1 Human genes 0.000 description 2
- 101710182998 Transcription factor COE1 Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000004504 adult stem cell Anatomy 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003519 mature b lymphocyte Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000008663 renal system process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
- 206010000159 Abnormal loss of weight Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 230000014503 B cell lineage commitment Effects 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710204837 Envelope small membrane protein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 101000601724 Homo sapiens Paired box protein Pax-5 Proteins 0.000 description 1
- 101000612671 Homo sapiens Pulmonary surfactant-associated protein C Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 101710145006 Lysis protein Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 108010045055 PAX5 Transcription Factor Proteins 0.000 description 1
- 102000005613 PAX5 Transcription Factor Human genes 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 102100040971 Pulmonary surfactant-associated protein C Human genes 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 101150078250 Tcf3 gene Proteins 0.000 description 1
- 108010057966 Thyroid Nuclear Factor 1 Proteins 0.000 description 1
- 102000002658 Thyroid Nuclear Factor 1 Human genes 0.000 description 1
- 102000003848 Uteroglobin Human genes 0.000 description 1
- 108090000203 Uteroglobin Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000000649 b-lymphocyte subset Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 229940064366 hespan Drugs 0.000 description 1
- 229940027278 hetastarch Drugs 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008938 immune dysregulation Effects 0.000 description 1
- 238000011502 immune monitoring Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- XEPXGZZWVKNRGS-GQYPCLOQSA-N n-[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]octanamide Chemical compound CCCCCCCC(=O)NC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XEPXGZZWVKNRGS-GQYPCLOQSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000013009 nonpyrogenic isotonic solution Substances 0.000 description 1
- 230000001662 opsonic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000011947 six minute walk test Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/5052—Cells of the immune system involving B-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- the present invention relates to methods of administering therapeutically effective amounts of isolated populations of allogeneic mesenchymal stem cells to effect cellular and humoral immunity in subjects suffering from non-ischemic dilated cardiomyopathy.
- the present invention also relates to methods of administering therapeutically effective amounts of isolated populations of allogeneic mesenchymal stem cells to effect cellular and humoral immunity in subjects suffering from symptoms of aging frailty.
- Aging frailty poses a very concerning problem for the overall health and well- being of individuals and is characterized as a syndrome of multisystem physiological dysregulation. Aging frailty is a geriatric syndrome characterized by weakness, low physical activity, slowed motor performance, exhaustion, and unintentional weight loss. See Yao, X. et al, Clinics in Geriatric Medicine 27(7 ⁇ :79-87 (2011). Furthermore, there are many studies showing a direct correlation between aging frailty and inflammation. See Hubbard, R E. et al, Biogerontoiogy 11 (5):6i5-(A ⁇ (2010).
- Immunosenescence is characterized by a low grade, chronic systemic inflammatory state known as inflammaging. See Franceshi, C. et al, Annals of the New York Academy of Sciences 908:244-254 (2000). This heightened inflammatory state or chronic inflammation found in aging and aging frailty leads to immune dy sregulation and a complex remodeling of both innate and adaptive immunity.
- the T cell and B cell repertoire is skewed resulting in an increase in CD8 + T effector memory cells re- expressing CD45ra (TEMRA) and in the CD19 + late/exhausted memory B cells, and a decrease in the CD8 1 Naive T cells, and in the switched memory B cells (CD27 + ).
- TEMRA CD45ra
- Inflammaging has received considerable attention because it proposes a link between immune changes and a number of diseases and conditions (such as aging frailty) common in old age.
- Circulating inflammatory mediators such as cytokines and acute phase proteins are markers of the low-grade inflammation observed to increase with aging.
- pro-inflammatory cytokines e.g., TNF- ⁇ , IL-6
- CSR reduced class switch recombination
- Immunoglobulin isotype switching is crucial for a proper immune response as the effector functions differ in each isotype.
- a key player in CSR and somatic hypermutation (SHM) is the enzyme, activation-induced cytidine deaminase (AID), encoded by the Aicda gene.
- AID's basic function in CSR and SHM is to initiate breaks in the DNA by converting cytosines to uracils in the switch and variable regions of immunoglobulins.
- E47 encoded by the Tcfe2a (E2A) gene, is a transcription factor belonging to the class I basic helix loop helix (bHLH) proteins, also known as E proteins.
- E47 Without E47 expression, the B cell specific transcription factors EBF1 (early B cell factor) and Pax-5 (paired box protein) are not expressed. Both E47 and Pax-5 are key transcription factors in early development for the B cell lineage and mature B cell function. See Hagman J. el al., Immunity 27(1):%- ⁇ Q (2007); Horcher M. et al, Immunity 14(6) J79-790 (2001); Riley R.L. et al, Seminars in Immunology 17(5).330-336 (2005).
- the Pax-5 gene encodes the B cell lineage specific activator protein (BSAP) that is expressed at all stages of B cell differentiation, but not in terminally differentiated B cells.
- BSAP B cell lineage specific activator protein
- Pax-5 controls B cell commitment by repressing B lineage inappropriate genes and activating B cell specific genes making Pax-5 the B cell gatekeeper and is exclusively expressed in the B lymphoid lineage from the committed pro-B cell to the mature B cell stage.
- the B cell specific transcription factor, Pax-5 is not only highly important in early B cell development and B cell lineage commitment, it is also involved in CSR.
- TNF-a the amount of TNF-a made: (1) depends on the amount of system inflammation and (2) impairs the ability of the same B cells to be stimulated with mitogens or antigens. See Frasca, D. et al., Journal of Immunology 188(1): ⁇ 9-2&6 (2012). Thus, the immune response in subjects suffering from aging frailty is impaired for a number of reasons.
- NIDCM Non-Ischemic Dilated Cardiomyopathy
- NIDCM Non-ischemic dilated cardiomyopathy
- Mesenchymal stem cells are multipotent cells able to migrate to sites of injury, while also being immunoprivileged by not detectably expressing major histocompatibility complex class II (MHC-II) molecules, and expressing MHC-I molecules at low levels.
- MHC-II major histocompatibility complex class II
- allogeneic mesenchymal stem cells hold great promise for therapeutic and regenerative medicine, and have been repeatedly shown to have a high safety and efficacy profile in clinical trials for multiple disease processes. See Hare, J.M.
- mesenchymal stem cells are also a potential source of multiple cell types for use in tissue engineering. See Gong Z. et al. Methods in Mol. Bio. 698:279-294 (2011); Price, A.P. et al, Tissue Engineering Part A 76(8/2581-2591 (2010); and Togel F. etal, Organogenesis 7(2/96-100 (2011).
- Mesenchymal stem cells have immuno-modulatory capacity. They control inflammation and the cytokine production of lymphocytes and myeloid-derived immune cells without evidence of immunosuppressive toxicity' and are hypo-immunogenic. See Bernardo M.E. etal, Cell Stem Cell 75( ⁇ /392-402 (2013).
- Mesenchymal stem cells also have the capacity to differentiate not only into cells of mesodermal origin, but into cells of endodermal and ectodermal origin. See Le Blanc K. et al, Exp. Hematol. 37(70/890-896 (2003).
- mesenchymal stem cells cultured in airway growth media differentiate to express lung-specific epithelial markers, e.g., surfactant protein-C, Clara cell secretory protein, and thyroid transcription factor-1.
- lung-specific epithelial markers e.g., surfactant protein-C, Clara cell secretory protein, and thyroid transcription factor-1. See Jiang Y. et al. Nature 418(6893)A ⁇ -49 (2002) and Kotton D.N. et al, Development 728(24/5181-5188 (2001).
- mesenchymal stem cells are reported in the literature to exert a suppressive effect on antibody production as well as proliferation and maturation of B cells. See Uccelli, A. et al. Trends in Immunology 28(5):2 ⁇ 9-226 (2007). Mesenchymal stem cells are also reported to inhibit the generation and function of antigen presenting cells. See Hoogduijn M.J. et al, Int. Immunopharmacology I0(12):1496-1500 (2010). Finally, mesenchymal stem cells are reported to suppress CD4 + and CD8 + T cell proliferation. See Ghannam S. et al, Stem Cell Res. & Ther. 1:2 (2010).
- the present inventors discovered a method of treating non-ischemic dilated cardiomyopathy in a subject, comprising administering a therapeutically effective amount of a population of isolated allogeneic human mesenchymal stem cells to a subject in need thereof.
- the present inventors also discovered a method of treating symptoms of aging frailty in a subject, comprising administering a therapeutically effective amount of a population of isolated allogeneic human mesenchymal stem cells to a subject in need thereof.
- the present inventors identified several biomarkers specific for non-ischemic dilated cardiomyopathy and aging frailty including, but not limited to, the levels of exhausted B cells (CD19 + , CD27 “ , lgD " ), the levels of switched memory B cells (CD19 + , CD27 high , IgD-), the levels of B-cells expressing intracellular TNF- ⁇ , the levels of early activated T-cells (CD3 + , CD69 4 ), the levels of chronic activated T-cells (CD3 + , CD25 + ), the levels of Temra cells (CD45RA + , CCR7 " ), the CD4 + :CD8 + T cell ratio, and the TNF-a concentration in serum.
- the levels of exhausted B cells CD19 + , CD27 “ , lgD "
- the levels of switched memory B cells CD19 + , CD27 high , IgD-
- the levels of B-cells expressing intracellular TNF- ⁇ the levels of early activated
- One aspect of the invention relates to a method of treating non-ischemic dilated cardiomyopathy in a subject, comprising administering a therapeutically effective amount of a population of isolated allogeneic human mesenchymal stem cells to a subject in need thereof, wherein the number of exhausted B cells (CD19 + , CD27 " , IgD " ) in a sample of the subject' serum decreases by at least 25% as compared to the number of exhausted B cells in a sample of the subject's serum prior to administration of the population of isolated allogeneic human mesenchymal stem cells, thereby treating the non-ischemic dilated cardiomyopathy.
- Another aspect of the invention relates to a method of treating non-ischemic dilated cardiomyopathy in a subject, comprising administering a therapeutically effective amount of a population of isolated allogeneic human mesenchymal stem cells to a subject in need thereof, wherein the number of switched memory B cells (CD19 + , CD27 high , IgD " ) in a sample of the subject's serum increases by at least 100% as compared to the number of switched memory B cells in a sample of the subject's serum prior to administration of the population of isolated allogeneic human mesenchymal stem cells, thereby treating the nonischemic dilated cardiomyopathy.
- the number of switched memory B cells CD19 + , CD27 high , IgD "
- Another aspect of the invention relates to a method of treating non-ischemic dilated cardiomyopathy in a subject, comprising administering a therapeutically effective amount of a population of isolated allogeneic human mesenchymal stem cells to a subject in need thereof, wherein the number of B-cells expressing intracellular TNF-a in a sample of the subject's serum decreases by at least 30% as compared to the number of B-cells expressing intracellular TNF-a in a sample of the subject's serum prior to administration of the population of isolated allogeneic human mesenchymal stem cells, thereby treating the nonischemic dilated cardiomyopathy.
- Another aspect of the invention relates to a method of treating non-ischemic dilated cardiomyopathy in a subject, comprising administering a therapeutically effective amount of a population of isolated allogeneic human mesenchymal stem cells to a subject in need thereof, wherein the number of early activated T-cells (CD3 + , CD69 + ) in a sample of the subject's serum decreases by at least 30% as compared to the number of early activated T- cells in a sample of the subject's serum prior to administration of the population of isolated allogeneic human mesenchymal stem cells, thereby treating the non-ischemic dilated cardiomyopathy.
- Another aspect of the invention relates to a method of treating non-ischemic dilated cardiomyopathy in a subject, comprising administering a therapeutically effective amount of a population of isolated allogeneic human mesenchymal stem cells to a subject in need thereof, wherein the number of chronic activated T-cells (CD3 + , CD25 + ) in a sample of the subject's serum decreases by at least 70% as compared to the number of chronic activated T-Cells in a sample of the subject's serum prior to administration of the population of isolated allogeneic human mesenchymal stem cells, thereby treating the non-ischemic dilated cardiomyopathy.
- Another aspect of the invention relates to a method of treating non-ischemic dilated cardiomyopathy in a subject, comprising administering a therapeutically effective amount of a population of isolated allogeneic human mesenchymal stem cells to a subject in need thereof, wherein the number of Temra cells (CD45RA f , CCR7 ' ) in a sample of the subject's serum decreases by at least 40% as compared to the number of Temra cells in a sample of the subject's serum prior to administration of the population of isolated allogeneic human mesenchymal stem cells, thereby treating the non-ischemic dilated cardiomyopathy.
- Another aspect of the invention relates to a method of treating non-ischemic dilated cardiomyopathy in a subject, comprising administering a therapeutically effective amount of a population of isolated allogeneic human mesenchymal stem cells to a subject in need thereof, wherein the TNF-a concentration in a sample of the subject's serum decreases by at least 80% as compared to the TNF-a concentration in a sample of the subject's serum prior to administration of the population of isolated allogeneic human mesenchymal stem cells, thereby treating the non-ischemic dilated cardiomyopathy.
- Another aspect of the invention relates to a method of treating symptoms of aging frailty in a subject, comprising administering a therapeutically effective amount of a population of isolated allogeneic human mesenchymal stem cells to a subject in need thereof, wherein the number of exhausted B cells (CD19 + , CD27 " , IgD " ) in a sample of the subject' serum decreases by at least 10% as compared to the number of exhausted B cells in a sample of the subject's serum prior to administration of the population of isolated allogeneic human mesenchymal stem cells, thereby treating the symptoms of aging frailty.
- Another aspect of the invention relates to a method of treating symptoms of aging frailty in a subject, comprising administering a therapeutically effective amount of a population of isolated allogeneic human mesenchymal stem cells to a subject in need thereof, wherein the number of switched memory in a sample of the subject's serum increases by at least 75% as compared to the number of switched memory B cells in a sample of the subject's serum prior to administration of the population of isolated allogeneic human mesenchymal stem cells, thereby treating the symptoms of aging frailty.
- Another aspect of the invention relates to a method of treating symptoms of aging frailty in a subject, comprising administering a therapeutically effective amount of a population of isolated allogeneic human mesenchymal stem cells to a subject in need thereof, wherein the number of B-cells expressing intracellular TNF-a in a sample of the subject's serum decreases by at least 60% as compared to the number of B-cells expressing intracellular TNF-a in a sample of the subject's serum prior to administration of the population of isolated allogeneic human mesenchymal stem cells, thereby treating the symptoms of aging frailty.
- Another aspect of the invention relates to a method of treating symptoms of aging frailty in a subject, comprising administering a therapeutically effective amount of a population of isolated allogeneic human mesenchymal stem cells to a subject in need thereof, wherein the number of early activated T-cells (CD3 + , CD69 + ) in a sample of the subject's serum decreases by at least 30% as compared to the number of early activated T-cells in a sample of the subject's serum prior to administration of the population of isolated allogeneic human mesenchymal stem cells, thereby treating the symptoms of aging frailty.
- Another aspect of the invention relates to a method of treating symptoms of aging frailty in a subject, comprising administering a therapeutically effective amount of a population of isolated allogeneic human mesenchymal stem cells to a subject in need thereof, wherein the number of chronic activated T-cells (CD3 + , CD25 + ) in a sample of the subject's serum decreases by at least 75% as compared to the number of chronic activated T-Cells in a sample of the subject's serum prior to administration of the population of isolated allogeneic human mesenchymal stem cells, thereby treating the symptoms of aging frailty.
- Another aspect of the invention relates to a method of treating symptoms of aging frailty in a subject, comprising administering a therapeutically effective amount of a population of isolated allogeneic human mesenchymal stem cells to a subject in need thereof, wherein the number of Temra cells (CD45RA + , CCR7 " ) in a sample of the subject's serum decreases by at least 20% as compared to the number of Temra cells in a sample of the subject's serum prior to administration of the population of isolated allogeneic human mesenchymal stem cells, thereby treating the symptoms of aging frailty.
- Another aspect of the invention relates to a method of treating symptoms of aging frailty in a subject, comprising administering a therapeutically effective amount of a population of isolated allogeneic human mesenchymal stem cells to a subject in need thereof, wherein the TNF-a concentration in a sample of the subject's serum decreases by at least 50% as compared to the TNF-a concentration in a sample of the subject's serum prior to administration of the population of isolated allogeneic human mesenchymal stem cells, thereby treating the symptoms of aging frailty.
- Another aspect of the invention relates to a method of treating symptoms of aging frailty in a subject, comprising administering a therapeutically effective amount of a population of isolated allogeneic human mesenchymal stem cells to a subject in need thereof, wherein the CD4 + :CD8 + T cell ratio in a sample of the subject's serum increases by at least 100% as compared to the CD4 + :CD8 + T cell ratio in a sample of the subject's serum prior to administration of the population of isolated allogeneic human mesenchymal stem cells, thereby treating the symptoms of aging frailty
- the subject is a human. In another embodiment of the invention, the subject is a human who exhibits infiammaging.
- the mesenchymal stem cells are bone marrow-derived mesenchymal stem cells. In one embodiment of the invention, the mesenchymal stem cells do not express STRO-1. In another embodiment of the invention, the mesenchymal stem cells do not express CD45. In another embodiment of the invention, the mesenchymal stem cells do not express fibroblast surface markers or have a fibroblast morphology. In another embodiment of the invention, the mesenchymal stem cells are not genetically manipulated.
- the isolated population of allogeneic mesenchymal stem cells is administered in a single dose. In another embodiment of the invention, the isolated population of allogeneic mesenchymal stem cells is administered in multiple doses, e.g., two or more doses. In another embodiment of the invention, the isolated population of allogeneic mesenchymal stem cells is administered at least yearly.
- the isolated population of allogeneic mesenchymal stem cells is administered systemically. In one embodiment of the invention, the isolated population of allogeneic mesenchymal stem cells is administered by infusion or direct injection. In one embodiment of the invention, the isolated population of allogeneic mesenchymal stem cells is administered intravenously, intraarterially, intramuscularly, intraperitoneally, subcutaneously, intradermally, orally, transendocardially, or intranasally. In a further embodiment, the isolated population of allogeneic mesenchymal stem cells is administered intravenously. In a further embodiment, the isolated population of allogeneic mesenchymal stem cells is administered intramuscularly.
- the isolated population of allogeneic mesenchymal stem cells is administered at a dose of about 20x10 6 mesenchymal stem cells. In another embodiment of the invention, the isolated population of allogeneic mesenchymal stem cells is administered at a dose of about lOOxlO 6 mesenchymal stem cells. In another embodiment of the invention, the isolated population of allogeneic mesenchymal stem cells is administered at a dose of about 200x10 6 mesenchymal stem cells.
- the isolated population of allogeneic mesenchymal stem cells are obtained from a human donor and wherein a step of MHC matching of the human donor to the subject is not employed prior to the administration of the isolated population of allogeneic mesenchymal stem cells to the subject.
- Another aspect of the invention relates to a method of evaluating cellular and humoral immunity status in a subject, comprising:
- correlating step comprises assigning a likelihood of one or more future changes in immune status to the subject based on the assay result(s); and (4) treating the subject based on the predetermined subpopulation of individuals to which the subject is assigned, wherein the treatment comprises administration of one or more additional doses of an isolated population of allogeneic human mesenchymal stem cells.
- Another aspect of the invention relates to a method of evaluating cellular and humoral immunity status in a subject, comprising:
- CD3 + , CD69 + chronic activated T-cells (CD3 + , CD25 + ), Temra cells (CD45RA + , CCR7 " ), the CD4 + :CD8 + T cell ratio, and serum TNF-a by introducing the serum sample obtained from the subject into an assay instrument which (i) contacts the serum sample with one or more antibodies which specifically bind for detection the biomarker(s) which are assayed, and (ii) generates one or more assay results indicating of binding of each biomarker which is assayed to a respective antibody to provide one or more assay results;
- the correlating step comprises assigning a likelihood of one or more future changes in immune status to the subject based on the assay result(s);
- the treatment comprises administration of one or more additional doses of an isolated population of allogeneic human mesenchymal stem cells.
- one or more future changes in immune status comprise one or more of an increase in the number of exhausted B cells (CD 19* CD27 “ , IgD " ), a decrease in the number of switched memory B cells
- an increase in the number of B-cells expressing intracellular TNF-a an increase in the number of early activated T-cells (CD3 + , CD69*), an increase in the number of chronic activated T-cells (CD3 + , CD25 1 ), an increase in the number of Temra cells (CD45RA , CCR7 " ), a decrease in the CD4 + :CD8 + T cell ratio, and an increase in serum TNF-a.
- Another aspect of the invention relates to an in vitro method of determining efficacy of treatment of non-ischemic dilated cardiomyopathy in a subject comprising: detennining the levels of one or more biomarkers selected from the group consisting of exhausted B cells (CD19 + , CD27 " , IgD ), switched memory B cells (CD19 + , CD27 high , IgD ), B-cells expressing intracellular TNF-a, early activated T-cells (CD3 + , CD69*), chronic activated T-cells (CD3 + , CD25 + ), Temra cells (CD45RA + , CCR7 " ), and the TNF-a concentration in serum obtained from the subject before and after administration of a population of isolated allogeneic human mesenchymal stem cells to the subject, and comparing the levels of the one or more biomarkers in the serum obtained before and after administration of the population of isolated human mesenchymal stem cells, wherein treatment is efficacious if
- the number of exhausted B cells decreases by at least 25% as compared to the number of exhausted B cells prior to administration of the population of isolated allogeneic human mesenchymal stem cells
- the number of switched memory B ( , , g ) increases by at least 100% as compared to the number of switched memory B cells prior to administration of the population of isolated allogeneic human mesenchymal stem cells
- the number of B-cells expressing intracellular TNF-a decreases by at least 30% as compared to the number of B-cells expressing intracellular TNF-a prior to administration of the population of isolated allogeneic human mesenchymal stem cells
- the number of early activated T-cells decreases by at least 30% as compared to the number of early activated T-cells prior to administration of the population of isolated allogeneic human mesenchymal stem cells
- the number of chronic activated T-cells decreases by at least 70% as compared to the number of chronic activated T-Cells prior to administration of the population of isolated allogeneic human mesenchymal stem cells
- the number of Temra cells decreases by at least 40% as compared to the number of Temra cells prior to administration of the population of isolated allogeneic human mesenchymal stem cells, and/or
- the TNF-a concentration in a sample of the subject's serum decreases by at least 80% as compared to the TNF-a concentration in a sample of the subject's serum prior to administration of the population of isolated allogeneic human mesenchymal stem cells.
- Another aspect of the invention relates to an in vitro method of determining efficacy of treatment of symptoms of aging frailty in a subject comprising: determining the levels of one or more biomarkers selected from the group consisting of exhausted B cells (CD19 + , CD27 ⁇ IgD ), switched memory B cells (CD19 + , CD27 high , IgD * ), B-cells expressing intracellular TNF-a, early activated T-cells (CD3 + , CD69 + ), chronic activated T-cells (CD3 + , CD25 + ), Temra cells (CD45RA + , CCR7 " ), the CD4 + :CD8 + T cell ratio, and the TNF-a concentration in serum obtained from the subject before and after administration of a population of isolated allogeneic human mesenchymal stem cells to the subject, and comparing the levels of the one or more biomarkers in the serum obtained before and after administration of the population of isolated human mesenchymal stem cells, wherein treatment is
- the number of exhausted B cells decreases by at least 10% as compared to the number of exhausted B cells prior to administration of the population of isolated allogeneic human mesenchymal stem cells
- the number of switched memory B cells increases by at least 75% as compared to the number of switched memory B cells prior to administration of the population of isolated allogeneic human mesenchymal stem cells
- the number of B-cells expressing intracellular TNF-a decreases by at least 60% as compared to the number of B-cells expressing intracellular TNF-a prior to administration of the population of isolated allogeneic human mesenchymal stem cells
- the number of early activated T-cells decreases by at least 30% as compared to the number of early activated T-cells prior to administration of the population of isolated allogeneic human mesenchymal stem cells
- the number of chronic activated T-cells decreases by at least 75% as compared to the number of chronic activated T-Cells prior to administration of the population of isolated allogeneic human mesenchymal stem cells
- the number of Temra cells decreases by at least 20% as compared to the number of Temra cells prior to administration of the population of isolated allogeneic human mesenchymal stem cells
- the TNF-a concentration in a sample of the subject's serum decreases by at least 50% as compared to the TNF-a concentration in a sample of the subject's serum prior to administration of the population of isolated allogeneic human mesenchymal stem cells, and/or
- the CD4+:CD8+ T cell ratio in a sample of the subject's serum increases by at least 100% as compared to the CD4+:CD8+ T cell ratio in a sample of the subject's serum prior to administration of the population of isolated allogeneic human mesenchymal stem cells.
- Another aspect of the invention relates to the use in vitro of the levels of exhausted B cells (CD19 + , CD27 “ , IgD " ), the levels of switched memory B cells (CD19 + , CD27 hi8h , IgD " ), the levels of B-cells expressing intracellular TNF- ⁇ , the levels of early activated T-cells , the levels of chronic activated T-cells ( the levels of Temra cells and the TNF-a concentration in serum for determining whether treatment for non-ischemic dilated cardiomyopathy is efficacious.
- Another aspect of the invention relates to the use in vitro of the levels of exhausted B cells the levels of switched memory B cells the ievels of B-cells expressing intracellular TNF- ⁇ , the levels of early activated T-cells the levels of chronic activated T-cells (CD3 + , CD25 1 ), the levels of Temra cells (CD45RA + , CCR7 " ), the CD4 + :CD8 + T cell ratio, and the TNF-a concentration in serum for determining whether treatment for aging frailty is efficacious.
- FIG. 1 is a Consort Diagram for a randomized, double-blinded, placebo- controlled study investigating the use of allogeneic mesenchymal stem cells for the treatment of older individuals with frailty.
- FIG. 2 provides baseline patient characteristics for subjects enrolled in the randomized, double-blinded, placebo-controlled study investigating the use of allogeneic mesenchymal stem cells for the treatment of older individuals with frailty.
- FIG. 3 shows a decrease in TNF-a in older subjects administered allogeneic human mesenchymal stem cells.
- FIG. 4 shows a decrease in early activated T cells expressing CD69 in older subjects administered allogeneic human mesenchymal stem cells.
- FIG. 5 shows a decrease in the numbers of chronic/late activated T cells expressing CD2S in older subjects administered allogeneic human mesenchymal stem cells.
- FIG. 6 shows measurements of CD8+ T cells in older subjects administered allogeneic human mesenchymal stem cells.
- FIG. 7 shows an increase in the ratio of CD47CD8 1 T cells in older subjects administered allogeneic human mesenchymal stem cells.
- FIG. 8 shows an increased immunosenescence score in patients with aging frailty who received two infusions of human mesenchymal stem cells.
- FIG. 9 shows a correlation between baseline serum TNF-a and baseline B cells expressing IC TNF-a .
- FIG. 10 provides the % of B cells expressing IC TNF-a in Young Control BL, Low TNF:IC TNF BL, and High TNF:IC TNF BL.
- FIG. 11 provides the % of Switch Memory B cells in Young Control BL, Low TNF:SwMem B cells BL, and High TNF:SwMem B cells BL.
- FIG. 12 provides the % of Exhausted B cells in Young Control BL, Low TNF:Exh B cells BL, and High TNF:Exh B cells BL.
- FIG. 13 provides the % of Temra cells in Young Control BL, Low TNFiTemra cells BL, and High TNF:Temra cells BL.
- FIG. 14 provides the CD4 + /CD8 + T cell ratio in Young Control BL, Low TNF:CD4:CD8 BL, and High TNF:CD4:CD8 BL.
- FIG. 15 provides the absolute change of serum TNF-a in pg/ml in Placebo Control, Low TNF-a, and High TNF-a.
- FIG. 16 shows a correlation between baseline serum TNF-a and the change in serum TNF-a.
- FIG. 17 shows the absolute change of B cells expressing IC TNF-a in Placebo Control, Low TNF-a, and High TNF-a.
- FIG. 18 shows a correlation between serum TNF-a and change in B cells expressing IC TNF-a.
- FIG. 19 shows the absolute change of % of Switch Memory B cells in Placebo Control, Low TNF-a, and High TNF-a.
- FIG. 20 shows the absolute change of % of Exhausted B cells in Placebo Control, Low TNF-a, and High TNF-a.
- FIG. 21 shows the absolute change of % of Temra T cells in Placebo Control, Low TNF-a, and High TNF-a
- FIG. 22 shows a correlation between the change in serum TNF-a and the change in Temra T cells.
- FIG. 23 shows the absolute change in the CD4 + /CD8 + T cell ratio in Placebo Control, Low TNF- ⁇ , and High TNF-a.
- FIG. 24 shows a correlation between the change in CD4 + /CD8 + T cell ratio and the change in Temra T cells.
- the present invention is directed to methods of treating non-ischemic dilated cardiomyopathy in a subject, comprising administering a therapeutically effective amount of a population of isolated allogeneic human mesenchymal stem cells to a subject in need thereof.
- the examples demonstrate that in vivo administration of isolated populations of allogeneic human mesenchymal stem cells result in an increase in the percentage of switched memory B cells and a decrease in exhausted B cells in subjects.
- the examples also demonstrate that in vivo administration of isolated allogeneic human mesenchymal stem cells results in an improvement in the CD4 + :CD8 + T cell ratio in subjects.
- the levels of B-cells expressing intracellular TNF-a, the levels of early activated T-cells (CD3 + , CD69*), the levels of chronic activated T-cells (CD3 4 , CD25 + ), the levels of Temra cells (CD45RA 4 , CCR7 ), and the TNF-a concentration in serum is reduced in subjects having received infusions of allogeneic human mesenchymal stem cells.
- the present inventors determined that isolated allogeneic human mesenchymal stem cells favorably altered several immunologic markers typically elevated in chronic inflammation. Restoration of immune competence has clinical relevant in subject who are of higher risk for co-morbid infectious disease.
- the present invention is directed to methods of treating symptoms of aging frailty in a subject, comprising administering a therapeutically effective amount of a population of isolated allogeneic human mesenchymal stem cells to a subject in need thereof.
- the examples demonstrate that in vivo administration of isolated populations of allogeneic human mesenchymal stem cells result in an increase in the percentage of switched memory B cells and a decrease in exhausted B cells in subjects.
- the examples also demonstrate that in vivo administration of isolated allogeneic human mesenchymal stem cells results in an improvement in the CD4 + :CD8 + T cell ratio in subjects.
- the levels of B-cells expressing intracellular TNF-a, the levels of early activated T- cells (CD3 + , CD69 + ), the levels of chronic activated T-cells (CD3 + , CD25 + ), the levels of Temra cells (CD45RA + , CCR7 " ), and the TNF-a concentration in serum is reduced in subjects having received infusions of allogeneic human mesenchymal stem cells. From these unexpected results, the present inventors determined that isolated allogeneic human mesenchymal stem cells are effective at reducing inflammaging, a prevalent feature in aging frailty.
- a therapeutically effective amount means an amount that stimulates a B- or T- cell dependent immune response. Such a response is characterized by the ability to elicit significant levels of IgG and opsonic activity.
- the dosage and number of doses (e.g., single or multiple dose) administered to the subject will vary depending upon a variety of factors, including the route of administration, patient conditions and characteristics (sex, age, body weight, health, size), extent of symptoms, concurrent treatments, frequency of treatment and the effect desired, and the like.
- the isolated population of allogeneic mesenchymal stem cells is administered as a single dose. In another embodiment, the isolated population of allogeneic mesenchymal stem cells is administered in multiple doses, e.g., two or more doses. In other embodiments, the isolated population of allogeneic mesenchymal stem cells is administered at least yearly.
- the administration of the isolated population of allogeneic mesenchymal stem cells is repeated, such as at least 1, 2, 3, 4, 5, 6, 8 months after the first administration of the isolated population of allogeneic mesenchymal stem cells, or repeated between 2-4, 2-6, 2-8, months after the first administration of the isolated population of allogeneic mesenchymal stem cells.
- the isolated population of allogeneic mesenchymal stem cells is administered at a dose of about l
- the isolated population of allogeneic mesenchymal stem cells is administered at a dose of about 20x10 6 mesenchymal stem cells. In a further embodiment, the isolated population of allogeneic mesenchymal stem cells is administered at a dose of about lOOxlO 6 mesenchymal stem cells. In yet a further embodiment, the isolated population of allogeneic mesenchymal stem cells is administered at a dose of about 200x10 6 mesenchymal stem cells. In further embodiments, the isolated population of allogeneic mesenchymal stem cells is administered
- the therapeutically effective amount of the isolated population of allogeneic mesenchymal stem cells is sufficient to increase the ratio of CD4 + :CD8 + T cells in a subject, such as to increase the ratio of CD4 + :CD8 + T cells by at least two-, three, four-, five-, or six-fold as compared to the ratio prior to administration of the isolated population of allogeneic mesenchymal stem cells, i.e., an increase in the ratio of CD4 + :CD8 + T cells by at least 100%, 200%, 300%, 400%, or 500%.
- the therapeutically effective amount of the isolated population of allogeneic mesenchymal stem cells is sufficient to increase the number of switched memory B cells (CD19 + , CD27 high , IgD " ) in a subject, such as to increase the number of switched memory B cells by at least two-, three-, four-, or five-fold as compared to the number prior to administration of the isolated population of allogeneic mesenchymal stem cells, i.e., an increase in the number of switched memory B cells (CD19 + , CD27 high ,, IgD " ) by at least 100%, 200%, 300%, or 400%.
- the number of switched memory B cells as compared to the number of such B cells prior to administration of the isolated population of allogeneic mesenchymal stem cells increases by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%.
- the therapeutically effective amount of the isolated population of allogeneic mesenchymal stem cells is sufficient to decrease the number of B cells expressing intracellular TNF-a in a subject, such as to decrease the number by at least two-, three-, four-, five-, or six-fold as compared to the number of such B cells prior to administration of the isolated population of allogeneic mesenchymal stem cells.
- the number of B cells expressing intracellular TNF-a as compared to the number of such B cells prior to administration of the isolated population of allogeneic mesenchymal stem cells decreases by at least 10%, 20%, 30%, 40%, 50%, or 60%.
- the therapeutically effective amount of the isolated population of allogeneic mesenchymal stem cells is sufficient to decrease the number of exhausted B cells (CD19 + , CD27 " , IgD " ) in a subject, such as to decrease the number of exhausted B cells by at least two- or three-fold as compared to the number prior to administration of the isolated population of allogeneic mesenchymal stem cells.
- the number of exhausted B cells as compared to the number of such B cells prior to administration of the isolated population of allogeneic mesenchymal stem cells decreases by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50%.
- the therapeutically effective amount of the isolated population of allogeneic mesenchymal stem cells is sufficient to decrease the number of early activated T-cells (CD3 + , CD69 + ) in a subject, such as to decrease the number of early activated T-cells by at least two- or three-fold as compared to the number prior to administration of the isolated population of allogeneic mesenchymal stem cells.
- the number of early activated T-cells as compared to die number of such T cells prior to administration of the isolated population of allogeneic mesenchymal stem cells decreases by at least 10%, 20%, 30%, 40%, or 50%.
- the therapeutically effective amount of the isolated population of allogeneic mesenchymal stem cells is sufficient to decrease the number of chronic activated T-cells (CD3 + , CD25 + ) in a subject, such as to decrease the number of chronic activated T-cells by at least two- or three-fold as compared to the number prior to administration of the isolated population of allogeneic mesenchymal stem cells.
- the number of chronic activated T-cells as compared to the number of such T cells prior to administration of the isolated population of allogeneic mesenchymal stem cells decreases by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%.
- the therapeutically effective amount of the isolated population of allogeneic mesenchymal stem cells is sufficient to decrease the number of Temra cells (CD45RA + , CCR7 " ) in a subject, such as to decrease the number of Temra cells by at least two- or three-fold as compared to the number prior to administration of the isolated population of allogeneic mesenchymal stem cells.
- the number of Temra cells as compared to the number of such Temra cells prior to administration of the isolated population of allogeneic mesenchymal stem cells decreases by at least 10%, 20%, 30%, 40%, or 50%.
- the therapeutically effective amount of the isolated population of allogeneic mesenchymal stem cells is sufficient to decrease the TNF-a concentration in a sample of the subject's serum, such as to decrease the TNF-a concentration by at least two- or three-fold as compared to the TNF-a concentration prior to administration of the isolated population of allogeneic mesenchymal stem cells.
- the concentration of TNF-a decreases by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%, as compared to the concentration of TNF-a prior to administration of the isolated population of allogeneic mesenchymal stem cells.
- Other aspects of the invention include methods for evaluating the cellular and humoral immunity status in subjects to determine if the subjects would benefit from the administration of an isolated population of allogeneic mesenchymal stem cells and treating a predetermined subpopulation of subjects based on biomarker data
- one or more assays could be performed to detect a non-ischemic dilated cardiomyopathy marker selected from the group of exhausted B cells (CD19 + , CD27 " , IgD " ), switched memory B cells (CD19 + , IgD " ), B-cells expressing intracellular TNF-a, early activated T-cells (CD3 4 , CD69 + ), chronic activated T-cells (CD3 f , CD25 4 ), Temra cells (CD45RA 4 , CCR7 ), and serum TNF-a.
- a non-ischemic dilated cardiomyopathy marker selected from the group of exhausted B cells (CD19 + , CD27 " , IgD " ), switched memory B cells (CD
- one or more assays could be performed to detect an aging frailty marker selected from the group of exhausted B cells (CD19 + , CD27 “ , IgD " ), switched memory B cells (CD19 + , IgD " ), B-cells expressing intracellular TNF- ⁇ , early activated T-cells (CD3 + , CD69 + ), chronic activated T-cells (CD3 + , CD25 + ), Temra cells (CD45RA + , CCR7 " ), the CD4 + :CD8 + T cell ratio, and serum TNF-a.
- an aging frailty marker selected from the group of exhausted B cells (CD19 + , CD27 “ , IgD " ), switched memory B cells (CD19 + , IgD " ), B-cells expressing intracellular TNF- ⁇ , early activated T-cells (CD3 + , CD69 + ), chronic activated T-cells (CD3 + , CD25 + ), Temra cells (CD
- treatment is demonstrated to be efficacious when the isolated population of allogeneic mesenchymal stem cells is sufficient to increase the ratio of CD4 + :CD8 + T cells in a subject, such as to increase the ratio of CD4 + :CD8 + T cells by at least two-, three, four-, five-, or six-fold as compared to the ratio prior to administration of the isolated population of allogeneic mesenchymal stem cells, i.e.. an increase in the ratio of CD4 + :CD8 + T cells by at least 100%, 200%, 300%, 400%, or 500%.
- treatment is demonstrated to be efficacious when the isolated population of allogeneic mesenchymal stem cells is sufficient to increase the number of switched memory B cells (CD19 + , CD27 high , IgD " ) in a subject, such as to increase the number of switched memory B cells by at least two-, three-, four-, or five-fold as compared to the number prior to administration of the isolated population of allogeneic mesenchymal stem cells, i.e., an increase in the number of switched memory B cells (CD19 + , C
- IgD " by at least 100%, 200%, 300%, or 400%.
- the number of switched memory B cells as compared to the number of such B cells prior to administration of the isolated population of allogeneic mesenchymal stem cells increases by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%.
- treatment is demonstrated to be efficacious when the isolated population of allogeneic mesenchymal stem cells is sufficient to decrease the number of B cells expressing intracellular TNF-a in a subject, such as to decrease the number by at least two-, three-, four-, five-, or six-fold as compared to the number of such B cells prior to administration of the isolated population of allogeneic mesenchymal stem cells.
- the number of B cells expressing intracellular TNF-a as compared to the number of such B cells prior to administration of the isolated population of allogeneic mesenchymal stem cells decreases by at least 10%, 20%, 30%, 40%, 50%, or 60%.
- treatment is demonstrated to be efficacious when the isolated population of allogeneic mesenchymal stem cells is sufficient to decrease the number of exhausted B cells (CD19 + , CD27 " , IgD " ) in a subject, such as to decrease the number of exhausted B cells by at least two- or three-fold as compared to the number prior to administration of the isolated population of allogeneic mesenchymal stem cells.
- the number of exhausted B cells as compared to the number of such B cells prior to administration of the isolated population of allogeneic mesenchymal stem cells decreases by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50%.
- treatment is demonstrated to be efficacious when the isolated population of allogeneic mesenchymal stem cells is sufficient to decrease the number of early activated T-cells (CD3 + , CD69*) in a subject, such as to decrease the number of early activated T-cells by at least two- or three-fold as compared to the number prior to administration of the isolated population of allogeneic mesenchymal stem cells.
- the number of early activated T-cells as compared to the number of such T cells prior to administration of the isolated population of allogeneic mesenchymal stem cells decreases by at least 10%, 20%, 30%, 40%, or 50%.
- treatment is demonstrated to be efficacious when the isolated population of allogeneic mesenchymal stem cells is sufficient to decrease the number of chronic activated T-cells (CD3 + , CD25 4 ) in a subject, such as to decrease the number of chronic activated T-cells by at least two- or three-fold as compared to the number prior to administration of the isolated population of allogeneic mesenchymal stem cells.
- the number of chronic activated T-cells as compared to the number of such T cells prior to administration of the isolated population of allogeneic mesenchymal stem cells decreases by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%.
- treatment is demonstrated to be efficacious when the isolated population of allogeneic mesenchymal stem cells is sufficient to decrease the number of Temra cells (CD45RA 1 , CCR7 " ) in a subject, such as to decrease the number of Temra cells by at least two- or three-fold as compared to the number prior to administration of the isolated population of allogeneic mesenchymal stem cells.
- the number of Temra cells as compared to the number of such Temra cells prior to administration of the isolated population of allogeneic mesenchymal stem cells decreases by at least 10%, 20%, 30%, 40%, or 50%.
- treatment is demonstrated to be efficacious when the isolated population of allogeneic mesenchymal stem cells is sufficient to decrease the TNF-a concentration in a sample of the subject's serum, such as to decrease the TNF-a concentration by at least two- or three-fold as compared to the TNF-a concentration prior to administration of the isolated population of allogeneic mesenchymal stem cells.
- the concentration of TNF-a decreases by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%, as compared to the concentration of TNF-a prior to administration of the isolated population of allogeneic mesenchymal stem cells.
- administering a composition may be accomplished by oral administration, injection, infusion, parenteral, intravenous, mucosal, sublingual, intramuscular, intradermal, intranasal, intraperitoneal, intraarterial, subcutaneous absorption or by any method in combination with other known techniques.
- the isolated population of allogeneic mesenchymal stem cells is administered systemically.
- the isolated population of allogeneic mesenchymal stem cells is administered by infusion or direct injection.
- the isolated population of allogeneic mesenchymal stem cells is administered intramuscularly, intravenously, intraarteerially, intraperitoneally, subcutaneously, intradermally, orally, transendocardially, or intranasally.
- the isolated population of allogeneic mesenchymal stem cells is administered intramuscularly.
- the isolated population of allogeneic mesenchymal stem cells is administered intravenously.
- the term "subject" as used herein includes, but is not limited to, humans and non-human vertebrates such as wild, domestic, and farm animals. In some embodiments, the term refers to humans, such as elderly humans >65 years of age, or elderly humans 60-95 years of age. In some embodiments, the human subject exhibits symptoms of aging frailty. In some embodiments, the human subject exhibits inflammaging.
- allogeneic refers to a cell that is of the same animal species but genetically different in one or more genetic loci as the animal that becomes the "recipient host.” This usually applies to cells transplanted from one animal to another non-identical animal of the same species.
- the phrase "in need thereof means that the subject has been identified as having a need for the particular method or treatment. In some embodiments, the identification can be by any means of diagnosis. In any of the methods and treatments described herein, the subject can be in need thereof. In some embodiments, the subject is in an environment or will be traveling to an environment in which a particular disease, disorder, or condition is prevalent.
- Cells are referred to herein as being positive or negative for certain markers.
- a cell can be negative for CD45, which can also be referred to as CD45 " .
- the superscript notation " " "” refers to a cell that is negative for the marker linked to the superscript.
- a marker with the " + " refers to a cell that is positive for that marker.
- a cell that is referenced as "CD8 + " is positive for CDS.
- a "+” can also be used to reference the marker as positive.
- a "-" can also be used to reference the marker as negative.
- stem cell refers to a cell from the embryo, fetus, or adult that has, under certain conditions, the ability to reproduce itself for long periods or, in the case of adult stem cells, throughout the life of the organism. It also can give rise to specialized cells that make up the tissues and organs of the body.
- Mesenchymal stem cells are the formative pluripotent blast cells found inter alia in bone marrow, blood, dermis, and periosteum that are capable of differentiating into any kind of the specific types of mesenchymal or connective tissues ⁇ i.e., the tissues of the body that support the specialized elements; particularly adipose, osseous, cartilaginous, elastic, and fibrous connective tissues) depending upon various influences from bioactive factors, such as cytokines.
- mesenchymal stem cells are isolated from bone marrow of adult humans.
- the cells are passed through a density gradient to eliminate undesired cell types.
- the cells can be plated and cultured in appropriate media.
- the cells are cultured for at least one day or about three to about seven days, and removing non-adherent cells. The adherent cells can then be plated and expanded.
- Placenta is an excellent readily available source for mesenchymal stem cells.
- mesenchymal stem cells can be derivable from adipose tissue and bone marrow stromal cells are speculated to be present in other tissues. While there are dramatic qualitative and quantitative differences in the organs from which adult stem cells can be derived, the initial differences between the cells may be relatively superficial and balanced by the similar range of plasticity thej' exhibit.
- Homogeneous human mesenchymal stem cell compositions which serve as the progenitors for all mesenchymal cell lineages.
- Mesenchymal stem cells are identified by specific cell surface markers which are identified with unique monoclonal antibodies.
- the homogeneous mesenchymal stem cell compositions are obtained by positive selection of adherent marrow or periosteal cells which are free of markers associated with either hematopoietic or differentiated mesenchymal cells.
- These isolated mesenchymal cell populations display epitopic characteristics associated with only mesenchymal stem cells, have the ability to regenerate in culture without differentiating, and have the ability to differentiate into specific mesenchymal lineages when either induced in vitro or placed in vivo at a site of inflammation.
- pluri potent mesenchymal stem cells are separated from other cells in the bone marrow or other mesenchymal stem cell source.
- Bone marrow cells may be obtained from iliac crest, femora, tibiae, spine, rib, or other medullary spaces.
- Other spaces of human mesenchymal stem cells include embryonic yolk sac, placenta, umbilical cord, fetal and adolescent skin, and blood.
- the human mesenchymal stem cells are identified by the absence of markers.
- human mesenchymal stem cells useful in the invention include those that are negative for STRO-1 and/or negative for CD45.
- human mesenchymal stem cells useful in the invention include those that do not express fibroblast surface markers or have a fibroblast morphology.
- the present invention is directed to a method of enhancing a subject's cellular or humoral immune response, comprising administering to the subject therapeutically effective amounts of an isolated population of human mesenchymal stem cells.
- the mesenchymal stem cells are not genetically manipulated.
- the mesenchymal stem cells are obtained from a human donor and wherein a step of MHC matching of the human donor to the subject is not employed prior to the administration of the isolated population of human mesenchymal stem cells.
- compositions for use in the invention may be formulated using any suitable method.
- Formulation of cells with standard pharmaceutically acceptable carriers and/or excipients may be carried out using routine methods in the pharmaceutical art. The exact nature of a formulation will depend upon several factors including the cells to be administered and the desired route of administration. Suitable types of formulation are fully described in Remington's Pharmaceutical Sciences, 19 th Edition, Mack Publishing Company, Eastern Pennsylvania, USA.
- compositions may be prepared together with a physiologically acceptable carrier or diluent.
- a physiologically acceptable carrier or diluent typically, such compositions are prepared as liquid suspensions of cells.
- the cells may be mixed with an excipient which is pharmaceutically acceptable and compatible with the active ingredient.
- excipients are, for example, water, saline, dextrose, glycerol, of the like and combinations thereof
- the pharmaceutical compositions of the invention may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance effectiveness.
- the adjuvant comprises human serum albumin (HSA).
- PlasmaLyte ATM This is a sterile, nonpyrogenic isotonic solution for intravenous administration.
- Each 100 mL contains 526 mg of Sodium Chloride, USP (NaCl); 502 mg of Sodium Gluconate (CeHnNaO?); 368 mg of Sodium Acetate Trihydrate, USP 37 mg of Potassium Chloride, USP (KG); and 30 mg of Magnesium Chloride, USP It contains no antimicrobial agents.
- the pH is adjusted with sodium hydroxide. The pH is 7.4 (6.5 to 8.0).
- the mesenchymal stem cells are not genetically manipulated.
- the mesenchymal stem cells are cryopreserved.
- the mesenchymal stem cells can be suspended in cryoprotectant consisting of Hespan® (6% hetastarch in 0.9% sodium chloride) supplemented with 2% HSA and 5% DMSO and then aliquoted into cryopreservation containers for placement in vapor phase nitrogen freezers.
- the mesenchymal stem cells may be provided in PlasmaLyte ATM supplemented with 1% HSA.
- Baseline assessments included chemistry and hematology laboratories, echocardiography, and chest, abdominal and pelvic computed tomography scans.
- hMSCs Human Mesenchymal Stem Cells
- All allogeneic and autologous human mesenchymal stem cells were manufactured at the University of Miami ISO. See, e.g., Golpanian, S. et al, Physiol. Rev. 96:1127-68 (2016) and Mushtaq, M. et al, J. Cardio. Trans. Res. 7:769-80 (2014). Allogeneic human mesenchymal stem cells were derived from Caucasian male donors mean age 25.4 ⁇ 3.3 years and were between 80 to 90% viable at the time of TESI. The auto- hMSCs were from 11 males with a mean age of 58.0 ⁇ 9.9 and six females with a mean age of 55.0 ⁇ 12.4 years.
- Injection sites were selected to prioritize safety of the TESI procedure and to distribute sites throughout the accessible myocardial territories. Considerations for site selection included avoidance of the ventricular apex, and optimization of catheter stability prior to needle extension.
- cPRA results showed that 67% of alio and 92% of auto recipients had no reaction to low cPRA (0-20% cPRA). Twenty-seven % of alio and 8% of auto had a moderate cPRA (21-79% cPRA), and one subject (7%) receiving alio MSCs had a high cPRA response (+80% cPRA).
- FIG. 1 is a Consort Diagram.
- FIG. 2 provides baseline patient characteristics.
- FIGs. 3-7 illustrate the impact of allogeneic human MSCs on immune biomarkers.
- FIG. 3 shows a decrease TNF-a in subjects administered human MSCs. Both early and late/chronic T cell activation decreases after allogeneic MSC treatment.
- FIG. 4 shows a decrease in early activated T cells expressing CD69 in subjects administered human MSCs.
- FIG. 5 shows a decrease in the numbers of chronic/late activated T cells expressing CD25 in subjects administered human MSCs.
- FIG. 7 shows an increase in the ratio of CD4 + /CD8 + T cells in subjects administered human MSCs.
- Table 10 are the total Scores for each patient that includes different time-points as well as averages among the patients.
- the immunosenescence Score improves in subjects with aging frailty after the first injection of human mesenchymal stem cells and continues to stay in an improved state after a second injection of human mesenchymal stem cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662421048P | 2016-11-11 | 2016-11-11 | |
PCT/US2017/061031 WO2018089752A1 (en) | 2016-11-11 | 2017-11-10 | Methods of using human mesenchymal stem cells to effect cellular and humoral immunity |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3538114A1 true EP3538114A1 (en) | 2019-09-18 |
Family
ID=60655047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17812104.2A Pending EP3538114A1 (en) | 2016-11-11 | 2017-11-10 | Methods of using human mesenchymal stem cells to effect cellular and humoral immunity |
Country Status (11)
Country | Link |
---|---|
US (1) | US20190290698A1 (es) |
EP (1) | EP3538114A1 (es) |
JP (2) | JP7276664B2 (es) |
KR (1) | KR20190084091A (es) |
CN (1) | CN110691600B (es) |
AU (1) | AU2017358042A1 (es) |
CA (1) | CA3043594A1 (es) |
IL (1) | IL266561B2 (es) |
TW (2) | TW201831681A (es) |
WO (1) | WO2018089752A1 (es) |
ZA (1) | ZA201903574B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110691600B (zh) | 2016-11-11 | 2024-04-16 | 美商生命科学有限公司 | 使用人类间充质干细胞以实现细胞免疫及体液免疫的方法 |
AU2019374898A1 (en) * | 2018-11-08 | 2021-06-24 | University Of Miami | Method of determining responsiveness to cell therapy in dilated cardiomyopathy |
CN111568927A (zh) * | 2020-05-23 | 2020-08-25 | 湖南源品细胞生物科技有限公司 | 一种msc用于调节记忆b细胞数量的应用 |
KR20230066407A (ko) | 2020-09-08 | 2023-05-15 | 롱에버론 인코포레이티드 | 동종이계 중간엽 줄기 세포를 이용한 알츠하이머병 치료 |
WO2023009537A1 (en) | 2021-07-26 | 2023-02-02 | Longeveron Inc. | Use of mesenchymal stem cells in treatment of juvenile hypoplastic left heart syndrome |
AU2022343620A1 (en) | 2021-09-10 | 2024-01-18 | Longeveron Inc. | Treatment of aging frailty comprising administering bone marrow derived mesenchymal stem cells |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPP977899A0 (en) * | 1999-04-15 | 1999-05-13 | Monash University | Improvement of t cell mediated immunity |
WO2006124827A2 (en) * | 2005-05-13 | 2006-11-23 | University Of Miami | Molecular dissection of cellular responses to alloantigen or autoantigen in graft rejection and autoimmune disease |
EP1937309A4 (en) * | 2005-09-14 | 2010-01-20 | Univ Columbia | CD8 + T LYMPHOCYTES REGULATORS INDUCED BY ANTI-CD3 ANTIBODIES |
US8501704B2 (en) | 2005-11-08 | 2013-08-06 | Sarepta Therapeutics, Inc. | Immunosuppression compound and treatment method |
US20120269774A1 (en) * | 2006-09-21 | 2012-10-25 | Medistem Laboratories, Inc | Allogeneic stem cell transplants in non-conditioned recipients |
AU2009259053B2 (en) | 2008-06-13 | 2013-12-12 | University College Cardiff Consultants Limited | Novel adult progenitor cell |
CN101690731B (zh) * | 2009-09-09 | 2013-07-10 | 中国人民解放军海军总医院 | 脐带华通胶源间充质干细胞在制备心力衰竭细胞移植材料中的应用 |
BR112013004917A2 (pt) * | 2010-08-31 | 2016-09-20 | Cook General Biotechnology Llc | terapias de células tronco alogênicas sistêmicas para tratamento de doenças em animais. |
JP5333508B2 (ja) * | 2011-04-22 | 2013-11-06 | コニカミノルタ株式会社 | 画像処理システム、ジョブ実行方法およびジョブ実行プログラム |
CN102908364A (zh) * | 2012-11-14 | 2013-02-06 | 青岛奥克生物开发有限公司 | 一种间充质干细胞注射液及其制备方法和在制备治疗儿童扩张型心肌病药物中的应用 |
KR20150111945A (ko) * | 2013-01-04 | 2015-10-06 | 테바 파마슈티컬 인더스트리즈 리미티드 | 글라티라머 아세테이트 관련 완제의 특성조사 |
EP2972368B1 (en) * | 2013-03-15 | 2019-07-24 | TiGenix, S.A.U. | Lymphocyte biomarkers for determining the clinical response to cell therapy |
WO2014203267A2 (en) * | 2013-06-17 | 2014-12-24 | Kasiak Research Pvt. Ltd. | Method for isolation, purification and industrial scale expansion of human adipose tissue derived mesenchymal stem cells |
US20190224240A1 (en) * | 2016-01-11 | 2019-07-25 | Cardiocell, Llc | Cell therapy for the treatment of non-ischemic heart failure |
CN110691600B (zh) | 2016-11-11 | 2024-04-16 | 美商生命科学有限公司 | 使用人类间充质干细胞以实现细胞免疫及体液免疫的方法 |
-
2017
- 2017-11-10 CN CN201780080636.3A patent/CN110691600B/zh active Active
- 2017-11-10 AU AU2017358042A patent/AU2017358042A1/en active Pending
- 2017-11-10 EP EP17812104.2A patent/EP3538114A1/en active Pending
- 2017-11-10 TW TW106138911A patent/TW201831681A/zh unknown
- 2017-11-10 TW TW111122170A patent/TWI820753B/zh active
- 2017-11-10 JP JP2019524319A patent/JP7276664B2/ja active Active
- 2017-11-10 WO PCT/US2017/061031 patent/WO2018089752A1/en unknown
- 2017-11-10 US US16/348,756 patent/US20190290698A1/en active Pending
- 2017-11-10 IL IL266561A patent/IL266561B2/en unknown
- 2017-11-10 KR KR1020197016501A patent/KR20190084091A/ko not_active Application Discontinuation
- 2017-11-10 CA CA3043594A patent/CA3043594A1/en active Pending
-
2019
- 2019-06-04 ZA ZA2019/03574A patent/ZA201903574B/en unknown
-
2022
- 2022-04-11 JP JP2022065222A patent/JP7491964B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
US20190290698A1 (en) | 2019-09-26 |
CA3043594A1 (en) | 2018-05-17 |
IL266561A (en) | 2019-07-31 |
CN110691600A (zh) | 2020-01-14 |
TWI820753B (zh) | 2023-11-01 |
TW202237819A (zh) | 2022-10-01 |
IL266561B1 (en) | 2024-02-01 |
ZA201903574B (en) | 2020-12-23 |
JP2019534307A (ja) | 2019-11-28 |
JP7276664B2 (ja) | 2023-05-18 |
AU2017358042A1 (en) | 2019-05-30 |
IL266561B2 (en) | 2024-06-01 |
WO2018089752A1 (en) | 2018-05-17 |
JP7491964B2 (ja) | 2024-05-28 |
TW201831681A (zh) | 2018-09-01 |
KR20190084091A (ko) | 2019-07-15 |
CN110691600B (zh) | 2024-04-16 |
JP2022106755A (ja) | 2022-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018089752A1 (en) | Methods of using human mesenchymal stem cells to effect cellular and humoral immunity | |
AU2021203382B2 (en) | Therapeutic pooled blood apoptotic cell preparations and uses thereof | |
Häusermann et al. | Cutaneous graft-versus-host disease: a guide for the dermatologist | |
WO2017076924A1 (en) | Mesenchymal stem cell-derived exosomes and their uses | |
IL260858A (en) | Zenchymal stem cells as vaccine aids and methods of use | |
WO2014089397A1 (en) | Compositions and methods of treating and preventing pulmonary fibrosis | |
CN117500914A (zh) | 富集的调节性t细胞的群体及其生产方法 | |
NZ794290A (en) | Methods of using human mesenchymal stem cells to effect cellular and humoral immunity | |
NZ794292A (en) | Methods of using human mesenchymal stem cells to effect cellular and humoral immunity | |
US20230167410A1 (en) | Prevention of recurrent miscarriages through administration of fibroblasts and fibroblast-educated paternal cells | |
CN117377755A (zh) | 包含调节性t细胞的组合物及其使用方法 | |
JP2023522931A (ja) | ポテンシーアッセイ | |
Iachininoto et al. | Physicians Poster Sessions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190529 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40014250 Country of ref document: HK |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: LONGEVERON INC. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20220218 |